SEC Form 10-Q filed by scPharmaceuticals Inc.
$SCPH
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | $20.00 | Buy | Craig Hallum |
| 12/1/2022 | $25.00 | Outperform | Cowen |
| 10/21/2022 | $14.00 | Buy | Jefferies |
| 10/11/2022 | $11.00 | Mkt Perform → Outperform | SVB Leerink |
| 8/2/2022 | $10.00 | Buy | Maxim Group |
| 9/9/2021 | $6.00 | Market Perform | SVB Leerink |
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX® to expand the indication to include trea
Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
S-8 - scPharmaceuticals Inc. (0001604950) (Filer)
10-K - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the
Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at 4:30pm ET BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare th
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00
Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00
Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00